Stock listing

NASDAQ:LBRX LB Pharmaceuticals Inc Stock

Home listing (NASDAQ) of LB Pharmaceuticals Inc

Follow LB Pharmaceuticals Inc into a list and get an email when it puts out news.

Share price · NASDAQ:LBRX

$38.85 USD -1.21 (-3.0%)

Close on Nov 20, 2026

Past year +146.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$38.57 – $40.67 USDNov 20, 2026
Volume
302,942 sharesNov 20, 2026
Market cap
$1.26B USDAt the close on Nov 20, 2026 · price × 32.36M shares outstanding
52-week range
$15.19 – $50.16 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$14.95M USDMedian day 354,370 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
LB Pharmaceuticals Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LBRX · Home$38.85 USD-1.21 (-3.0%)302,942$39.23$40.67$38.57$40.06Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LBRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$38.85-1.21-3.0%$39.23$40.67$38.57302,942
$40.06-0.24-0.6%$40.31$41.71$38.72356,411
$40.30-2.69-6.3%$43.20$44.01$38.83396,092
$42.99-0.020.0%$43.07$43.95$42.08597,257
$43.01+0.55+1.3%$42.66$43.43$41.03330,168
$42.46-2.25-5.0%$44.37$44.37$41.88438,110
$44.71-0.23-0.5%$45.21$45.46$44.30341,759
$44.94-0.18-0.4%$44.38$45.68$43.46377,881
$45.12+3.11+7.4%$43.05$45.77$41.54472,299
$42.01+3.92+10.3%$38.53$42.29$38.52476,193
$38.09-2.76-6.8%$41.01$41.01$38.02354,370
$40.85+0.52+1.3%$41.40$41.40$38.75365,762
$40.33+1.29+3.3%$39.65$41.40$39.15245,821
$39.04-0.66-1.7%$40.56$40.91$38.24466,446
$39.70-0.45-1.1%$40.10$41.24$39.13429,435
$40.15+0.32+0.8%$39.80$40.76$39.23400,678
$39.83+0.19+0.5%$39.53$40.38$38.49201,736
$39.64+0.30+0.8%$39.14$40.35$38.58236,345
$39.34+0.61+1.6%$41.05$41.05$38.45275,975
$38.73-0.69-1.8%$39.25$39.73$38.26188,600
$39.42+0.19+0.5%$39.12$41.58$38.39230,900
$39.23-1.77-4.3%$41.10$41.24$39.04247,100
$41.00+2.19+5.6%$38.88$41.42$38.24388,400
$38.81+2.07+5.6%$36.91$40.10$36.03588,500
$36.74+0.05+0.1%$36.62$37.37$36.06724,700
$36.69+2.69+7.9%$34.54$37.43$34.50976,600
$34.00-0.79-2.3%$34.10$35.51$33.88362,700
$34.79-1.14-3.2%$36.10$36.10$34.44296,800
$35.93-1.29-3.5%$37.26$37.43$34.54491,500
$37.22+2.61+7.5%$35.01$38.50$35.01642,600
$34.61+0.45+1.3%$33.83$35.73$33.13440,700
$34.16-0.10-0.3%$34.02$36.57$34.00385,000
$34.26-0.36-1.0%$35.25$35.59$33.73432,800
$34.62-2.37-6.4%$36.41$36.88$34.47494,500
$36.99-0.29-0.8%$37.72$38.82$36.75388,900
$37.28-1.10-2.9%$38.10$38.59$37.13278,900
$38.38+1.10+3.0%$37.61$39.23$37.34437,200
$37.28-0.61-1.6%$37.89$38.13$36.98713,400
$37.89+0.56+1.5%$37.24$38.17$36.57534,600
$37.33-0.47-1.2%$37.85$38.57$36.99398,900
$37.80-1.39-3.5%$39.13$39.39$37.56413,500
$39.19-3.50-8.2%$42.80$42.80$38.84481,700
$42.69-0.30-0.7%$43.40$43.40$41.21244,400
$42.99+0.52+1.2%$42.55$43.22$41.54310,200
$42.47+0.33+0.8%$42.22$42.54$41.39531,600
$42.14-0.43-1.0%$43.33$43.50$41.78314,500
$42.57-0.47-1.1%$43.37$43.94$42.17231,900
$43.04-1.80-4.0%$44.84$44.84$42.50320,500
$44.84+0.21+0.5%$44.95$45.72$44.55242,800
$44.63-1.62-3.5%$46.80$47.68$44.40208,400
$46.25-1.42-3.0%$47.20$47.20$45.50174,800
$47.67-1.72-3.5%$49.07$49.81$47.46190,100
$49.39+0.05+0.1%$48.53$49.62$47.15301,000
$49.34+1.82+3.8%$47.47$49.91$47.47206,000
$47.52-1.96-4.0%$48.88$48.91$46.72282,500
$49.48+2.38+5.1%$47.31$49.93$46.44518,400
$47.10-0.16-0.3%$47.21$48.21$46.92202,000
$47.26-0.47-1.0%$47.47$47.50$46.38386,900
$47.73-0.16-0.3%$47.64$49.25$46.37230,600
$47.89-0.275-0.6%$48.15$48.42$47.14256,100
$48.17-0.635-1.3%$48.71$48.71$47.21244,900
$48.80+0.59+1.2%$48.70$50.16$48.49217,000
$48.21+0.59+1.2%$47.88$49.06$46.83252,700
$47.62+0.39+0.8%$47.71$48.21$46.34225,800
$47.23-1.71-3.5%$48.51$48.86$46.90194,500
Ticker
NASDAQ:LBRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All LB Pharmaceuticals Inc news

LB Pharmaceuticals Inc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
Decks
16 decks · latest Nov 5, 2026

Where LB Pharmaceuticals Inc is listed

ListingExchangeCountryCurrency
NASDAQ:LBRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LBRXBOATSUnited StatesUSD

Valuation

Price/book 3.0× against a median of 3.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$858.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.81

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
Absci Corporation · NASDAQ:ABSIUS$1.30BUS$1.13Bn/a758×n/a5.9×n/a0.0×3.20
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Ocular Therapeutix, Inc. · NASDAQ:OCULUS$1.23BUS$774.9Mn/a15.4×n/a2.8×−648.6%0.2×1.35
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Median of the othersUS$1.23BUS$899.0M28.1×309×3.4×−327.8%0.0×1.37

Forecasts

8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
58.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.04 · 10 analysts

Team and board

Officers

OfficerRole
Heather TurnerChief Executive Officer, LB Pharmaceuticals
Joseph M. MillerChief Financial Officer
Gad SofferChief Operating and Business Officer
Minako PazderaGeneral Counsel
Christopher ZergebelSenior Vice President, Clinical Operations
Ellen RoseSenior Vice President, Corporate Affairs
James RawlsSenior Vice President, Regulatory Affairs
Richard A. SilvaSenior Vice President, Technical Operations
Kaya Pai PanandikerChief Commercial Officer
Susan G. KozauerChief Medical Officer

Board

DirectorRole
Rebecca LuseDirector
Rekha HemrajaniDirector
Scott GarlandChairman of the Board, LB Pharmaceuticals
Ran NussbaumDirector
Rob LenzMember
Robert R. RuffoloIndependent Director
William KaneDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+10.3%
Q2 2026Aug 11, 2026 · Before open−1.1%
Q1 2026May 15, 2026 · After close−6.5%
Q4 2025Mar 26, 2026 · After close−2.8%
Q3 2025Nov 6, 2025 · Before open−4.3%
Q2 2025Sep 3, 2025

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck35 slidesNov 5, 2026
Investor Presentation (October 2026)Investor deck35 slidesOct 27, 2026
Investor Day (October 2026)Investor day60 slidesOct 27, 2026
Investor Presentation (August 2026)Investor deck35 slidesAug 11, 2026
Investor Presentation (August 2026)Investor deck35 slidesAug 11, 2026
Investor Presentation (January 2025)Investor deck20 slidesJanuary 2025
Investor Presentation (December 2023)Investor deck26 slidesDecember 2023
Investor Presentation (September 2023)Investor deck26 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck33 slidesJune 2023
Investor Presentation (February 2023)Investor deck33 slidesFebruary 2023
All 16 decks
DeckKindSlidesDate
Investor Presentation (December 2022)Investor deck33 slidesDecember 2022
Investor Presentation (October 2022)Investor deck33 slidesOctober 2022
Investor Presentation (December 2021)Investor deck28 slidesDecember 2021
Investor Presentation (January 2019)Investor deck30 slidesJanuary 2019
Sachs Bio Capital USA Forum 2018Conference21 slidesMar 21, 2018
Technical Presentation (October 2017)Technical13 slidesOctober 2017

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$150M · US$34.94 a share · Leerink Partners +1
Dealers: Leerink Partners, Piper Sandler
Buyers: Adage Capital Partners, L.P.; BB Biotech; Caligan Partners; Commodore Capital; Deep Track Capital; Farallon Capital Management; Integral Health Asset Management; Janus Henderson Investors; Spruce Street Capital; StemPoint Capital LP
Use of proceeds: Expand LB-102 into new indications such as negative symptoms of schizophrenia and Alzheimer's agitation/psychosis, plus working capital and general purposes
Jul 29, 2026
Private placement of common stock and pre-funded warrants
Announced: about US$100M · US$21.17 a share · Leerink Partners +2
Dealers: Leerink Partners, Piper Sandler, Stifel
Buyers: Balyasny Asset Management L.P.; Caligan Partners; Commodore Capital; Deep Track Capital; Nantahala Capital; Pivotal bioVenture Partners; Spruce Street Capital; TCGX; Trails Edge Capital Partners
Use of proceeds: Fund a Phase 2 trial of LB-102 as adjunctive treatment for major depressive disorder, plus working capital and general corporate purposes
Feb 5, 2026
Public offering of common stock
Announced: US$285M · US$15 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Stifel (co-lead)
Sep 11, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Sep 10, 2025.

Price
US$15.00 a share
Shares offered
19,000,000 shares of common stock
Offering size
US$285 million
Underwriters' option
Up to 2,850,000 more shares
Listing
LBRX on the Nasdaq Global Market
Underwriters
Leerink Partners, Piper Sandler, Stifel · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 20, 2024
Filed publiclyAug 22, 2025
Amended onceSep 8, 2025
Shares registered with an exchangeSep 9, 2025
Declared effective by the SECSep 10, 2025
Final prospectus, with the priceSep 12, 2025

Open IPO · From the cover of the final prospectus (424B4) filed Sep 12, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Cost of revenue321.0K
Gross profit-321.0K
Research and development16.7M51.2M7.84M1.35M
Selling, general and administrative13.7M13.7M3.53M1.46M
Operating income-30.4M-64.8M-11.4M-2.81M
Depreciation and amortization321.0K91.0K4.00K2.00K
EBITDA-30.1M-64.7M-11.4M-2.81M
Interest expense04.83M2.15M
Income before tax-25.2M-63.1M-6.27M-14.3M
Income tax1.00K1.00K1.00K1.00K
Net income-25.2M-63.1M-6.28M-14.3M
Earnings per share, basic-3.13-176.15-1.77-4.05
Earnings per share, diluted-3.13-176.15

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents250.2M23.0M15.0M21.4M
Short-term investments45.0M5.02M28.3M0
Current assets308.4M28.9M45.6M21.5M
Property, plant and equipment1.58M1.86M
Total assets312.9M33.5M45.7M21.5M
Accounts payable2.13M2.32M1.39M156.0K
Current liabilities7.44M8.11M2.61M469.0K
Long-term debt24.1M
Total debt3.57M3.70M24.1M
Total liabilities11.6M13.8M80.1M50.3M
Shareholders' equity301.3M-94.6M-34.5M-28.8M
Shares outstanding25.3M251.7K3.54M3.54M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-35.2M-53.1M-12.1M-2.73M
Capital spending-52.0K-769.0K-25.0K0
Free cash flow-35.3M-53.8M-12.1M-2.73M
Cash from investing-39.9M23.2M-28.0M123.0K
Cash from financing302.6M38.3M33.7M23.0M
Change in cash227.5M8.50M-6.42M20.4M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 13, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveOct 6, 2026Other filingsSEC
POS AM · Amendment to an effective registrationOct 1, 2026Offer documentSEC
All 146 filings
FilingDateTypeFiled with
S-3ASR · Registration statementOct 1, 2026Offer documentSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
424B3 · ProspectusSep 15, 2026Offer documentSEC
8-K · Current reportSep 15, 2026Management or board changeSEC
3 · Initial statement of ownershipSep 14, 2026Insider tradeSEC
424B3 · ProspectusSep 3, 2026Offer documentSEC
8-K · Current reportSep 3, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
424B3 · ProspectusAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
424B3 · ProspectusJul 29, 2026Offer documentSEC
8-K · Current reportJul 29, 2026Material contractSEC
424B3 · ProspectusJul 22, 2026Offer documentSEC
8-K · Current reportJul 22, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 16, 2026Big-stake noticeSEC
424B3 · ProspectusJun 10, 2026Offer documentSEC
8-K · Current reportJun 10, 2026Management or board changeSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
424B3 · ProspectusJun 9, 2026Offer documentSEC
8-K · Current reportJun 9, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
424B3 · ProspectusMay 12, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 15, 2026Other filingsSEC
424B3 · ProspectusApr 14, 2026Offer documentSEC
CORRESP · Letter to the SECApr 10, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 10, 2026Other filingsSEC
S-1 · Registration statementApr 6, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 26, 2026Offer documentSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 16, 2026Management or board changeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 10, 2026Insider tradeSEC
8-K · Current reportMar 10, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
8-K · Current reportFeb 5, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 31, 2025Big-stake noticeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 18, 2025Insider tradeSEC
8-K · Current reportNov 13, 2025Material contractSEC
8-K · Current reportNov 12, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 17, 2025Big-stake noticeSEC
4 · Change in ownershipSep 29, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 29, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeSep 25, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 19, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeSep 19, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 18, 2025Big-stake noticeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
8-K · Current reportSep 12, 2025Current reportSEC
424B4 · ProspectusSep 12, 2025Offer documentSEC
3 · Initial statement of ownershipSep 11, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 11, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 11, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 11, 2025Other filingsSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringSep 10, 2025Offer documentSEC
S-8 · Registration statement for employee plansSep 10, 2025Offer documentSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2025Insider tradeSEC
CERT · Exchange's certificate of listingSep 10, 2025Other filingsSEC
CORRESP · Letter to the SECSep 9, 2025Other filingsSEC
CORRESP · Letter to the SECSep 9, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 9, 2025Other filingsSEC
S-1/A · Registration statement, amendedSep 8, 2025Offer documentSEC
CORRESP · Letter to the SECSep 3, 2025Other filingsSEC
CORRESP · Letter to the SECAug 22, 2025Other filingsSEC
S-1 · Registration statementAug 22, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 12, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 23, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedJul 23, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 2, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 24, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJun 24, 2024Offer documentSEC
UPLOAD · Letter from the SECJun 17, 2024Other filingsSEC
DRS · Draft registration statementMay 20, 2024Offer documentSEC
D/AJan 10, 2024Other filingsSEC
DSep 21, 2023Other filingsSEC
D/ANov 23, 2022Other filingsSEC
DNov 1, 2022Other filingsSEC
DJul 6, 2022Other filingsSEC
DSep 1, 2020Other filingsSEC
DDec 12, 2018Other filingsSEC
DAug 27, 2018Other filingsSEC
DMay 29, 2018Other filingsSEC
DApr 6, 2017Other filingsSEC
DDec 15, 2016Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from LB Pharmaceuticals Inc’s releases · as of Nov 3, 2026

Common shares
32,363,040
Fully diluted
32,363,040

Fully diluted

LineSharesAs of
Common shares32,363,040Nov 3, 2026

Share count over time

CountShares
Nov 3, 202632,363,040

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Deep Track Capital, LP3.35MUS$129MSep 30, 2026
BlackRock2.35MUS$90.1MSep 30, 2026
Ra Capital Management, L.P.2.21MUS$84.8MSep 30, 2026
Caligan Partners LP1.51MUS$49.6MSep 30, 2026
Vanguard1.45MUS$55.7MSep 30, 2026
JPMorgan1.44MUS$53.8MSep 30, 2026
Spruce Street Capital LP1.4MUS$53.9MSep 30, 2026
Commodore Capital LP1.28MUS$49.2MSep 30, 2026
Trails Edge Capital Partners, LP1.15MUS$44.1MSep 30, 2026
Fidelity1.1MUS$39.5MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Nantahala Capital Management, LLC1.07MUS$41.2MSep 30, 2026
Goldman Sachs964KUS$37MSep 30, 2026
Adage Capital Partners Gp, L.L.C.950KUS$36.5MSep 30, 2026
Balyasny Asset Management L.P.802KUS$30.8MSep 30, 2026
Vivo Capital, LLC800KUS$30.7MSep 30, 2026
Alyeska Investment Group, L.P.792KUS$30.4MSep 30, 2026
TCG Crossover Management, LLC765KUS$29.4MSep 30, 2026
Farallon Capital Management, L.L.C.741KUS$28.5MSep 30, 2026
Bellevue Group AG716KUS$27.5MSep 30, 2026
State Street705KUS$27.1MSep 30, 2026
Nan Fung Group Holdings Ltd631KUS$24.2MSep 30, 2026
Geode Capital624KUS$24MSep 30, 2026
Janus Henderson582KUS$22.3MSep 30, 2026
Jennison Associates LLC576KUS$22.1MSep 30, 2026
Integral Health Asset Management, LLC470KUS$18MSep 30, 2026
Great Point Partners LLC410KUS$15.8MSep 30, 2026
T. Rowe Price351KUS$13.5MSep 30, 2026
Boothbay Fund Management, LLC287KUS$10.4MSep 30, 2026
Candriam S.C.A.284KUS$10.9MSep 30, 2026
Logos Global Management LP250KUS$9.6MSep 30, 2026
UBS237KUS$9.09MSep 30, 2026
Citadel225KUS$8.64MSep 30, 2026
Schwab220KUS$8.43MSep 30, 2026
Baker Bros. Advisors LP200KUS$7.68MSep 30, 2026
Northern Trust194KUS$7.43MSep 30, 2026
HighVista Strategies LLC174KUS$6.67MSep 30, 2026
Millennium173KUS$6.63MSep 30, 2026
BNP Paribas167KUS$6.42MSep 30, 2026
Two Sigma161KUS$6.16MSep 30, 2026
Morgan Stanley116KUS$4.47MSep 30, 2026
Susquehanna106KUS$4.05MSep 30, 2026
Eversept Partners, LP92,850US$3.56MSep 30, 2026
Stempoint Capital LP91,757US$3.47MSep 30, 2026
Point72 Asset Management, L.P.91,309US$3.5MSep 30, 2026
XTX Topco Ltd89,619US$3.44MSep 30, 2026
Longbow Finance SA82,336US$3.16MSep 30, 2026
Wellington80,000US$3.07MSep 30, 2026
Nuveen70,388US$2.7MSep 30, 2026
NEXTBio Capital Management LP69,549US$2.67MSep 30, 2026
D. E. Shaw & Co., Inc.67,789US$2.6MSep 30, 2026

This page holds 50 of 140 holders. Open Shareholders

Funds

HolderSharesValueAs of
JPMorgan Small Cap Growth Fund693KUS$22.5MJun 30, 2026
Vanguard Total Stock Market Index Fund672KUS$21.8MJun 30, 2026
iShares Russell 2000 ETF582KUS$18.9MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio568KUS$15.9MMay 29, 2026
Vanguard Extended Market Index Fund279KUS$9.05MJun 30, 2026
Fidelity Small Cap Index Fund245KUS$9.82MJul 31, 2026
PGIM Jennison Health Sciences Fund231KUS$6.47MMay 29, 2026
JPMorgan Small Cap Blend Fund220KUS$7.15MJun 30, 2026
Select Biotechnology Portfolio188KUS$5.25MMay 31, 2026
Calamos Timpani Small Cap Growth Fund144KUS$5.78MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Extended Market Index Fund126KUS$3.53MMay 31, 2026
Schwab U.S. Small-Cap ETF116KUS$3.23MMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund110KUS$3.07MMay 31, 2026
iShares Russell 2000 Value ETF107KUS$3.49MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF105KUS$3.41MJun 30, 2026
iShares Russell 2000 Growth ETF99,716US$3.24MJun 30, 2026
Vanguard Russell 2000 Index Fund98,764US$2.76MMay 31, 2026
iShares Micro-Cap ETF75,231US$2.44MJun 30, 2026
iShares U.S. Pharmaceuticals ETF63,173US$2.05MJun 30, 2026
Schwab Small-Cap Index Fund54,176US$2.17MJul 31, 2026
Fidelity Total Market Index Fund46,559US$1.3MMay 31, 2026
Master Small Cap Index Series41,840US$1.36MJun 30, 2026
Carillon Chartwell Small Cap Fund38,729US$1.26MJun 30, 2026
Fidelity Series Total Market Index Fund37,181US$1.04MMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF35,986US$1.17MJun 30, 2026
Health Sciences Portfolio33,445US$1.09MJun 30, 2026
Carillon Chartwell Small Cap Growth Fund30,045US$975KJun 30, 2026
Nuveen Small Cap Blend Index Fund29,730US$1.19MJul 31, 2026
EQ/2000 Managed Volatility Portfolio24,276US$788KJun 30, 2026
Fidelity Nasdaq Composite Index Fund17,550US$491KMay 31, 2026
Fidelity Small Cap Value Index Fund16,543US$537KJun 30, 2026
LVIP State Street Small-Cap Index Fund16,000US$519KJun 30, 2026
Nuveen Equity Index Fund15,490US$621KJul 31, 2026
Schwab Total Stock Market Index Fund14,457US$579KJul 31, 2026
EQ/Small Company Index Portfolio13,300US$432KJun 30, 2026
Fidelity ZERO Total Market Index Fund13,015US$522KJul 31, 2026
PACE Small/Medium Co Growth Equity Investments12,918US$518KJul 31, 2026
Schwab U.S. Broad Market ETF12,556US$351KMay 31, 2026
EQ/AB Small Cap Growth Portfolio12,200US$396KJun 30, 2026
Avantis U.S. Small Cap Equity ETF11,605US$325KMay 31, 2026
Small Cap Index Fund11,286US$366KJun 30, 2026
Virtus Biotech Clinical Trials Etf10,936US$438KJul 31, 2026
Global X Russell 2000 ETF10,682US$428KJul 31, 2026
Vanguard Balanced Index Fund10,196US$331KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund10,170US$330KJun 30, 2026
U.S. Small Cap Equity Fund10,009US$401KJul 31, 2026
Fidelity Small Cap Growth Index Fund9,947US$323KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund9,545US$267KMay 31, 2026
Fidelity ZERO Extended Market Index Fund8,988US$360KJul 31, 2026
MetLife Russell 2000 Index Portfolio7,570US$246KJun 30, 2026

This page holds 50 of 125 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Deep Track Capital, LP11.70%3.35MFeb 6, 2025Schedule 13D
Ra Capital Management, L.P.8.70%2.21MDec 31, 2025Schedule 13G
BlackRock, Inc.6.30%1.8MJun 30, 2026Schedule 13G
Pontifax Management 4 G.P. (2015) Ltd.6.30%1.41MSep 12, 2025Schedule 13D
Commodore Capital LP5.80%1.9MSep 30, 2026Schedule 13G
Caligan Partners LP5.00%1.44MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Scott Garland
Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Jan 7, 2026); Olema Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); ALX Oncology Holdings Inc. (Chairman · Since at least Nov 28, 2022); Day One Biopharmaceuticals Inc (Director · Since at least Aug 16, 2021); Calithera Biosciences, Inc. (Director · Jul 10, 2020 – Jun 1, 2022 · Past); Portola Pharmaceuticals Inc (President and CEO, Director · Oct 8, 2018 – Jul 2, 2020 · Past); Karyopharm Therapeutics Inc. (Director · Nov 3, 2014 – Jun 6, 2019 · Past); Relypsa Inc (SVP & Chief Commercial Officer · Oct 31, 2014 – Sep 1, 2016 · Past); Exelixis, Inc. (EVP & Chief Commerical Officer · Oct 20, 2011 – Sep 18, 2013 · Past)
Chairman of the Board, LB Pharmaceuticals · Since at least Sep 10, 2025
Heather Turner
Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Lyell Immunopharma, Inc. (Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past)
Chief Executive Officer, Director · Since at least Sep 10, 2025
Rekha Hemrajani
Other companies: BioAge Labs, Inc. (Director · Since at least Apr 17, 2024); MaxCyte, Inc. (Non-Executive Director · Since at least Jun 29, 2022); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022)
Director · Since at least Sep 10, 2025
Joseph Miller
Other companies: Aurinia Pharmaceuticals Inc (Chief Financial Officer · Since at least Jan 1, 2021); Avalo Therapeutics, Inc. (Director · Jul 12, 2018 – Mar 31, 2022 · Past)
Chief Financial Officer · Since at least Sep 2, 2026
Robert Lenz
Other companies: NovaBridge Biosciences (Director · Since at least Mar 18, 2026); Neumora Therapeutics, Inc. (Head of R&D · Sep 14, 2023 – Feb 18, 2025 · Past)
Director · Since at least Mar 6, 2026
Ellen Rose
Other companies: Lyell Immunopharma, Inc. (Senior Vice President, Communications and Investor Relations · Since at least Dec 7, 2025)
Senior Vice President, Corporate Affairs · Since at least Oct 15, 2026
Ran Nussbaum
Other companies: Keros Therapeutics, Inc. (Director · Since at least May 30, 2024)
Director · Since at least Sep 10, 2025
Anna EramoChief Medical Officer · Since at least Sep 10, 2025
Christopher ZergebelSenior Vice President, Clinical Operations · Since at least Jun 30, 2026
Gad SofferChief Business Officer · Since at least Sep 10, 2025
All 22 people
PersonSeat
James RawlsSenior Vice President, Regulatory Affairs · Since at least Oct 14, 2025
Kaya Pai PanandikerChief Commercial Officer · Since at least Nov 12, 2025
Marc L PanoffSenior Vice President, Finance · Since at least Sep 10, 2025
Minako PazderaGeneral Counsel · Since at least Jan 21, 2026
Panandiker Kaya Kamlesh PaiChief Commercial Officer · Since at least Nov 10, 2025
Rebecca LuseDirector · Since at least Sep 10, 2025
Richard A. SilvaSenior Vice President, Technical Operations · Since at least Sep 10, 2025
Robert R. RuffoloIndependent Director · Since at least Nov 5, 2026
Rob LenzMember · Since at least May 12, 2026
Susan G. KozauerChief Medical Officer · Since at least Sep 14, 2026
William KaneDirector · Since at least Mar 26, 2026
Zachary PrenskyDirector · Since at least Sep 10, 2025

Open People

Log in to ask 6ix AI your own questions about LB Pharmaceuticals Inc.